Autism Clinical Trial
Official title:
An Open-label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism
Verified date | January 2014 |
Source | Forest Laboratories |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of autism in pediatric patients.
Status | Completed |
Enrollment | 102 |
Est. completion date | February 2013 |
Est. primary completion date | February 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Completed lead-in study MEM-MD-57A (NCT00872898) - A knowledgeable caregiver capable of providing reliable information about the patient's condition, able to attend all clinic visits with the patient Exclusion Criteria: - Patients with a concurrent medical condition that might interfere with the conduct of the study |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Forest Investigative Site 025 | Cambridge | Massachusetts |
United States | Forest Investigative Site 013 | Cleveland | Ohio |
United States | Forest Investigative Site 015 | Cleveland | Ohio |
United States | Forest Investigative Site 001 | Columbus | Ohio |
United States | Forest Investigative Site 014 | Hoffman Estates | Illinois |
United States | Forest Investigative Site 010 | Indianapolis | Indiana |
United States | Forest Investigative Site 024 | Jacksonville Beach | Florida |
United States | Forest Investigative Site 017 | Manhasset | New York |
United States | Forest Investigative Site 023 | Naperville | Illinois |
United States | Forest Investigative Site 019 | Oklahoma | Oklahoma |
United States | Forest Investigative Site 005 | Phoenix | Arizona |
United States | Forest Investigative Site 003 | Sacramento | California |
United States | Forest Investigative Site 021 | San Francisco | California |
United States | Forest Investigative Site 020 | Santa Ana | California |
United States | Forest Investigative Site 026 | Santa Ana | California |
United States | Forest Investigative Site 007 | St. Petersburg | Florida |
United States | Forest Investigative Site 002 | Stanford | California |
United States | Forest Investigative Site 011 | Toms River | New Jersey |
United States | Forest Investigative Site 006 | Voorhees | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Forest Laboratories | Merz Pharmaceuticals GmbH |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Patients Who Experienced a Treatment-emergent Adverse Event (TEAE) | Number of patients who experienced one or more TEAEs during the study | From Visit 1 (Week 1) to 30 days after Visit 8 (Week 48) | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05302167 -
Molehill Mountain Feasibility Study.
|
N/A | |
Completed |
NCT04167839 -
Effects of Sensory Diets on Children's Sensory Processing Skills, Psychosocial Skills, and Classroom Engagement
|
N/A | |
Terminated |
NCT04049981 -
Investigation of Mechanisms of Action in Superpower Glass
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06080087 -
Implementation Toolkit to Enhance EBP Among Marginalized Families
|
N/A | |
Recruiting |
NCT04107064 -
Achieving Steady Work Among Adults With Autism Through Specialized Employment Program
|
N/A | |
Completed |
NCT03206996 -
Exposure Therapy for Auditory Sensitivity in Autism
|
N/A | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Completed |
NCT05588570 -
Coaching Children With Anxiety and Autism Through Telehealth
|
N/A | |
Enrolling by invitation |
NCT06058104 -
Evaluating Efficacy of a Digital Game Therapeutic for Children With Autism
|
N/A | |
Completed |
NCT02847182 -
Cord Blood Infusion for Children With Autism Spectrum Disorder
|
Phase 2 | |
Completed |
NCT02911194 -
a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)
|
N/A | |
Withdrawn |
NCT02414451 -
Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response
|
N/A | |
Completed |
NCT03002363 -
The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance
|
Phase 1 | |
Completed |
NCT02536365 -
Sensory Integration Therapy in Autism: Mechanisms and Effectiveness
|
N/A | |
Completed |
NCT02720900 -
Prebiotic Intervention for Autism Spectrum Disorders
|
N/A | |
Completed |
NCT02708290 -
Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
|
||
Completed |
NCT02508922 -
Trial of Vitamin D3 Supplementation in Paediatric Autism
|
N/A | |
Recruiting |
NCT01836562 -
A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism
|
Phase 1/Phase 2 | |
Recruiting |
NCT02255565 -
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
|
Phase 4 | |
Completed |
NCT02154828 -
Clinical Evaluation of Integrative Practices Units Infant and Child Care for Unit Children With Typical or Atypical Autism (AUTISM)
|